Abstract library

4 results for "Nieto".
#1133 Prognosis of Stage IV Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to the WHO Classification and the Primary Tumor Location
Introduction: WHO classification of GEP-NET is used to predict prognosis, yet survival within each grade shows wide variation. We hypothesized that primary tumor location may be partially responsible of this variability.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: PhD Paula Jiménez-Fonseca
#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Keywords: sunitinib, PNET, Choi, RECIST
#1389 Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain
Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero
#1405 Capecitabine-Temozolomide in G3 Neuroendocrine Neoplasms
Introduction: There is no standard second line treatment for G3 neuroendocrine neoplasms (NENs). The sensitivity to platinum combinations of G3 NENs with a Ki67 < 50% remains unclear.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero